Wnt1-induced MAFK expression promotes osteosarcoma cell proliferation

Genetics and Molecular Research

Volumn 14, Issue 3, 2015, Pages 7315-7325

  Wang, R ^a   Zheng, J ^a   Zhang, D S ^a   Yang, Y H ^a   Zhao, Z F ^a  

^a The 117th Hospital of Chinese PLA   (China)

Author keywords

MAFK; Osteosarcoma; Proliferation; Wnt

Indexed keywords

MESSENGER RNA; TRANSCRIPTION FACTOR MAFK; WNT1 PROTEIN; MAFK PROTEIN, HUMAN; WNT1 PROTEIN, HUMAN;

ARTICLE; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MAFK GENE; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; BIOSYNTHESIS; BONE TUMOR; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; WNT SIGNALING PATHWAY;

BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MAFK TRANSCRIPTION FACTOR; OSTEOSARCOMA; RNA, MESSENGER; TRANSFECTION; WNT SIGNALING PATHWAY; WNT1 PROTEIN;

EID: 84936888118     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2015.July.3.7     Document Type: Article

References (28)

1. Bielack SS, Carrle D, Hardes J, Schuck A, et al. (2008). Bone tumors in adolescents and young adults. Curr. Treat. Options Oncol. 9: 67-80.
2. Blank V, Knoll JH and Andrews NC (1997). Molecular characterization and localization of the human MAFG gene. Genomics 44: 147-149.
3. Brand M, Ranish JA, Kummer NT, Hamilton J, et al. (2004). Dynamic changes in transcription factor complexes during erythroid differentiation revealed by quantitative proteomics. Nat. Struct. Mol. Biol. 11: 73-80.
4. Broadhead ML, Clark JC, Myers DE, Dass CR, et al. (2011). The molecular pathogenesis of osteosarcoma: a review. Sarcoma 2011: 959248.
5. Brun J, Dieudonne FX, Marty C, Muller J, et al. (2013). FHL2 silencing reduces Wnt signaling and osteosarcoma tumorigenesis in vitro and in vivo. PLoS One 8: e55034.
6. Chen B, Dodge ME, Tang W, Lu J, et al. (2009). Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat. Chem. Biol. 5: 100-107.
7. Chou AJ and Gorlick R (2006). Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev. Anticancer Ther. 6: 1075-1085.
8. Chou AJ, Geller DS and Gorlick R (2008). Therapy for osteosarcoma: where do we go from here? Paediatr. Drugs 10: 315-327.
9. Dhakshinamoorthy S and Jaiswal AK (2000). Small maf (MafG and MafK) proteins negatively regulate antioxidant response element-mediated expression and antioxidant induction of the NAD(P)H: Quinone oxidoreductase1 gene. J. Biol. Chem. 275: 40134-40141.
10. Francastel C, Magis W and Groudine M (2001). Nuclear relocation of a transactivator subunit precedes target gene activation. Proc. Natl. Acad. Sci. U. S. A. 98: 12120-12125.
11. Ghosh M, Brancato SJ, Agarwal PK and Apolo AB (2014). Targeted therapies in urothelial carcinoma. Curr. Opin. Oncol. 26: 305-320.
12. Gorjanacz M (2014). Nuclear assembly as a target for anti-cancer therapies. Nucleus 5: 47-55.
13. Hoang BH (2012). Wnt, osteosarcoma, and future therapy. J. Am. Acad. Orthop. Surg. 20: 58-59.
14. Itoh K, Chiba T, Takahashi S, Ishii T, et al (1997). An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun. 236: 313-322.
15. Kannan MB, Solovieva V and Blank V (2012). The small MAF transcription factors MAFF, MAFG and MAFK: current knowledge and perspectives. Biochim. Biophys. Acta 1823: 1841-1846.
16. Kansara M, Tsang M, Kodjabachian L, Sims NA, et al. (2009). Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J. Clin. Invest. 119: 837-851.
17. McQueen P, Ghaffar S, Guo Y, Rubin EM, et al. (2011). The Wnt signaling pathway: implications for therapy in osteosarcoma. Expert Rev. Anticancer Ther. 11: 1223-1232.
18. Ney PA, Andrews NC, Jane SM, Safer B, et al. (1993). Purification of the human NF-E2 complex: cDNA cloning of the hematopoietic cell-specific subunit and evidence for an associated partner. Mol. Cell Biol. 13: 5604-5612.
19. Nguyen T, Huang HC and Pickett CB (2000). Transcriptional regulation of the antioxidant response element. Activation by Nrf2 and repression by MafK. J. Biol. Chem. 275: 15466-15473.
20. Nishikawa K, Nakashima T, Takeda S, Isogai M, et al. (2010). Maf promotes osteoblast differentiation in mice by mediating the age-related switch in mesenchymal cell differentiation. J. Clin. Invest. 120: 3455-3465.
21. Nishizawa M, Kataoka K, Goto N, Fujiwara KT, et al. (1989). v-maf, a viral oncogene that encodes a "leucine zipper" motif. Proc. Natl. Acad. Sci. U. S. A. 86: 7711-7715.
22. Okita Y, Kamoshida A, Suzuki H, Itoh K, et al. (2013). Transforming growth factor-beta induces transcription factors MafK and Bach1 to suppress expression of the heme oxygenase-1 gene. J. Biol. Chem. 288: 20658-20667.
23. Siclari VA and Qin L (2010). Targeting the osteosarcoma cancer stem cell. J. Orthop. Surg. Res. 5: 78.
24. Siegel HJ and Pressey JG (2008). Current concepts on the surgical and medical management of osteosarcoma. Expert Rev. Anticancer Ther. 8: 1257-1269.
25. Trent JC (2008). Rapid evolution of the biology and treatment of sarcoma. Curr. Opin. Oncol. 20: 393-394.
26. Vinson C, Acharya A and Taparowsky EJ (2006). Deciphering B-ZIP transcription factor interactions in vitro and in vivo. Biochim. Biophys. Acta 1759: 4-12.
27. Yang J and Zhang W (2013). New molecular insights into osteosarcoma targeted therapy. Curr. Opin. Oncol. 25: 398-406.
28. Zhong L, Wang Y, Li W, Gu J, et al. (2014). Heme oxygenase-1 silencing increases the sensitivity of human osteosarcoma MG63 cells to arsenic trioxide. Mol. Cell Biochem. 392: 135-144.